In Phase C, individuals will obtain ABBV-744 and oral navitoclax. In Segment D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until finally disorder progression or perhaps the members are not able to tolerate the study drugs. Celastrol was identified to be a Myb inhibitor that suppressed C/EBPβ https://friedensreichc444ugs8.shoutmyblog.com/profile